Introduction {#Sec1}
============

Surgical patients are at increased risk of malnutrition, in particular, hyperglycemia^[@CR1]^. Nearly half of the patients who were receiving parenteral nutrition had hyperglycemia (PN) outside of the intensive care settings^[@CR2],[@CR3]^. Hyperglycemia is positively associated with increased hospital complications and mortality for patients receiving PN^[@CR4]^. Patients receiving PN with glycaemia above 180 mg/dL had increased death rates ranging from 2- to \>10-fold and increased complications than those with mean blood glucose levels less than 140 mg/dL^[@CR4]--[@CR6]^. Therefore, clinical practice guidelines and consensus statements recommend a blood glucose levels had points of 140--180 mg/dL patients who are receiving PN^[@CR7],[@CR8]^.

Prandial and neutral protamine Hagedorn (NPH) insulin administration was the usually preferring protocol in management of blood glucose in patients receiving PN. To providing better control of blood glucose control, researchers prefer to administer only part of insulin in the PN bag, and the other part of insulin administered subcutaneously^[@CR9]^.

Insulin dose is significantly increased during administration of PN for management of glycemic control in patients with type 2 diabetes (T2D)^[@CR10]^. The reason may partly be that patients needing PN support are associated with a raised level of stress, which leads to hyperglycemia in some patients^[@CR11]--[@CR13]^. In addition to this, the increased levels of cortisol and catecholamines induced by surgical procedures leading to significantly increased insulin resistance, also^[@CR14]^. Hyperglycemic, especially an acute glucose spike which triggers oxidative stress, and an over-production of peroxynitrite and nitrotyrosine^[@CR15]--[@CR17]^, is an independent risk factor for cardiovascular disease^[@CR18]^. This is significant factor to consider, and that makes it necessary to take steps to avoid blood glucose fluctuations during the management of PN. Continuous subcutaneous insulin infusion (CSII) is a safe therapy to smooth blood glycemic execution during the management of hyperglycemia either in newly diagnosed or in longstanding T2D patients^[@CR19]^.

Continuous Glucose Monitoring (CGM) monitoring of glucose concentrations every 5 min could be a useful method for discovering the 24-hrs glucose profiles in patients receiving PN. Using CGM data, clinicians could efficiently evaluate the glycemic control which might be an important factor to consider in decision-making^[@CR20]^.

However, it is unknown the efficacy of CSII therapy on glycemic variation in patients receiving PN outside of intensive units. In the current study, we performed 4-day CGM to assess the effect of CSII on blood glucose fluctuations in surgery patients receiving PN.

Results {#Sec2}
=======

Baseline characteristics {#Sec3}
------------------------

Between May 2017 and Aug 2017, a total of 102 patients were consecutively recruited for the study, and randomized to CSII therapy group (n = 50) and MDI group (n = 52). There were no significant demographic differences within groups at baseline, with the exception of body weight and BMI in MDI group were significantly lower than that in CSII group. Also, there were no differences in HbA~1c~, mean fasting blood glucose, and mean fasting plasma C-Peptide levels between groups (Table [1](#Tab1){ref-type="table"}).Table 1Demographic characteristics in subjects between groups at baseline.CSII Group (n = 50)MDI Group (n = 52)*P* valueSex (male)68.0%59.6%0.38Age (years)66.8 ± 9.165.3 ± 9.30.42Body weight (Kg)64.0 ± 8.960.1 ± 5.40.01Height (cm)165.7 ± 5.7163.9 ± 5.60.12BMI (kg/m^2^)23.34 ± 3.1522.34 ± 1.510.04Course (years)5.2 ± 3.05.7 ± 2.50.33HbA~1c~ (%)7.7 ± 1.48.2 ± 1.20.07FBG (mmol/L)9.6 ± 3.748.67 ± 1.830.11F C-peptide (ng/mL)1.7 ± 1.71.9 ± 0.90.59Operative site (S/I/P/L)40%/40%/4%/16%48.1%/32.7%/5.8%/13.5%0.80Data were presented as means ± SD. BMI: Body mass index, Course: Course of diabetes, FBG: Fasting blood Glucose level, F C-peptide: Fasting C-Peptide concentration, S: Stomach, I: Intestine, P: Pancreas, L: Liver.

All patients receiving PN therapy in both groups had had gastrointestinal surgery. There were no differences in surgery sites between the two groups (CSII group: stomach 40%/intestine 40%/pancreas 4%/liver 16%, MDI group: stomach 48.1%/intestine 32.7%/pancreas 5.8%/liver 13.5%, P \> 0.05).

Before operation, patients in the CSII group reached glycemic control in fewer days than those in the control group (2.23 ± 1.82 vs. 4.32 ± 1.17 days, P \< 0.05). In addition, patients in the CSII group needed similar daily insulin dose to maintain glycemic control compared to those in the MDI group (0.43 ± 0.22 vs. 0.46 ± 0.25 IU/Kg, P \> 0.05).

24-hrs Glycemic variation profiles {#Sec4}
----------------------------------

Patients receiving the CSII therapy had significantly decreased in the 24-hrs mean amplitude of glycemic excursions (MAGE), the standard deviation of MG (SDBG), SD, the coefficient of variation (CV%), the 24-hrs mean blood glucose (MBG), and the incremental area under the curve (AUC) \> 10 mmol/L compared to those in MDI group, respectively (all P \< 0.01). We did not observe any differences in the incremental AUC  \< 3.9 mmol/L between groups (P \> 0.05) (Table [2](#Tab2){ref-type="table"}). We also observed that subjects in the CSII group exhibited significantly lower hourly mean glucose levels compared to those in the MDI group, respectively (all P \< 0.05) (Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).Table 2Glycemic profiles between groups in study subjects at the endpoint.CSII Group (n = 50)MDI Group (n = 52)*P* value24 hrs-AUC \> 103.3(0.0,282.0)2024.5(574.4,3253.5)0.0024 hrs-AUC \< 3.90.0(0.0,0.0)0.0(0.0,9.9)0.8424 hrs-SD1.4 ± 1.02.5 ± 1.00.0024 hrs-MAGE3.7 ± 2.86.2 ± 3.00.0024 hrs-MBG7.0 ± 1.910.1 ± 2.40.0024 hrs- CV (%)17.6 ± 11.426.7 ± 11.90.0014 hrs-AUC \> 100.0(0.0,24.2)223.6(53.5,396.3)0.0014 hrs-AUC \< 3.90.0(0.0,0.0)0.0(0.0,0.0)0.9614 hrs-SD1.1 ± 0.92.1 ± 1.00.0014 hrs- CV (%)13.8 ± 9.921.7 ± 11.10.00Data were presented as means ± SD or IQR. 24-hrs: Glycemic profiles of 24-hrs, AUC \> 10: the incremental area under curve of glucose concentrations above 10 mmol/L (mmol/L per day), AUC \< 3.9: the incremental area under curve of glucose concentrations less than 3.9 mmol/L (mmol/L per day), SD: standard deviation (mmol/L), MAGE: mean amplitude of glycemic excursions (mmol/L), MBG: mean glucose concentration (mmol/L), CV: coefficient of variation (%), 14-hrs: Glycemic profiles of 14-hrs (During PN period).Table 3Hourly mean glucose concentration in subjects between groups at the endpoint.Time (O'clock)CSII Group (n = 50)MDI Group (n = 52)*P* value0000--0100 (mmol/L)7.7 ± 2.69.4 ± 3.40.010100--0200 (mmol/L)7.7 ± 2.79.2 ± 3.70.020200--0300 (mmol/L)7.7 ± 2.79.2 ± 3.90.030300--0400 (mmol/L)7.6 ± 2.89.0 ± 4.10.040400--0500 (mmol/L)7.6 ± 2.99.4 ± 4.00.010500--0600 (mmol/L)7.7 ± 3.19.5 ± 4.10.020600--0700 (mmol/L)7.6 ± 3.19.6 ± 4.00.010700--0800 (mmol/L)7.8 ± 3.110.3 ± 3.60.000800--0900 (mmol/L)8.4 ± 2.610.7 ± 3.50.000900--1000 (mmol/L)8.1 ± 2.210.1 ± 3.20.001000--1100 (mmol/L)7.8 ± 2.29.8 ± 3.00.001100--1200 (mmol/L)7.9 ± 2.210.0 ± 2.80.001200--1300 (mmol/L)7.9 ± 2.110.6 ± 2.80.001300--1400 (mmol/L)8.0 ± 2.310.9 ± 2.90.001400--1500 (mmol/L)7.9 ± 2.311.2 ± 3.30.001500--1600 (mmol/L)7.6 ± 2.210.8 ± 3.50.001600--1700 (mmol/L)7.7 ± 2.210.6 ± 3.90.001700--1800 (mmol/L)7.7 ± 2.110.6 ± 3.80.001800--1900 (mmol/L)7.6 ± 2.410.7 ± 3.70.001900--2000 (mmol/L)8.1 ± 2.310.7 ± 3.50.002000--2100 (mmol/L)8.1 ± 2.210.6 ± 3.10.002100--2200 (mmol/L)8.1 ± 2.410.2 ± 3.20.002200--2300 (mmol/L)7.9 ± 2.19.7 ± 3.20.002300--2400 (mmol/L)7.9 ± 2.29.3 ± 3.40.01Data were presented as means ± SD. Course: Course of diabetes, S: Stomach, I: Intestine, P: Pancreas, L: Liver.Figure 1The hourly glucose concentrations calculated from CGM in subjects between groups at the endpoint.

14-hrs Glycemic variation profiles (During PN time) {#Sec5}
---------------------------------------------------

To observe the impaction of dextrose containing in Fatemulsion, Aminoacids (17) And Glucose (11) Injection, we also analyzed glycemic profiles of patients during the PN period. Our CGM data showed that patients in CSII therapy had significant improvement in 14-hrs MBG, MAGE, SDBG, SD, GV(%), and the incremental AUC \>10 mmol/L compared to those in the MDI group, respectively (all P \< 0.01). We did not observe any patients who experienced hypoglycemia in either group (P \> 0.05) (Table [3](#Tab3){ref-type="table"}). In addition, patients in the CSII group had significantly lower hourly mean glucose levels when compared to those in the MDI group (all P \< 0.05) (Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}).

Glucose and insulin profile {#Sec6}
---------------------------

Patients receiving CSII therapy needed significantly less insulin to maintain glycemic control when compared to those in the MDI group (P \< 0.01) at the endpoint. Consistently, the basal and bolus insulin doses were also decreased in the CSII therapy group (P \< 0.01). However, in this trial, recruited patients in the CSII group had lower body weight compared to those in the MDI group. We further analyzed the insulin dose per Kg between groups. Our data showed that patients in the CSII group required significantly lower basal and bolus insulin doses (IU per Kg) when compared to the control group to maintain glycemic control at the endpoint, P \< 0.01. In addition to this, we also observed that patients who received bolus insulin doses which were required to maintain euglycemic control had their doses gradually decreased before the end point of PN. This was observed in both groups (1000--1600 *vs*. 1600--2000, 1600--2000 *vs*. 2000--2400, P \< 0.01, respectively) (Table [4](#Tab4){ref-type="table"}).Table 4Insulin dose required by patients to maintain glycemic control in subjects between groups at the endpoint.CSII Group (n = 50)MDI Group (n = 52)*P* valueTOD (IU)25.3 ± 5.032.3 ± 2.90.001000--2400 (IU)21.6 ± 4.126.1 ± 2.40.000000--1000 (IU)3.8 ± 1.26.2 ± 0.70.000000--1600 (IU)12.2 ± 2.016.2 ± 1.50.001600--2000 (IU)5.5 ± 1.47.4 ± 1.00.002000--2400 (IU)3.8 ± 1.12.5 ± 0.30.00TOD/Kg (IU/Kg)0.4 ± 0.10.5 ± 0.10.001000--2400 (IU/Kg)0.3 ± 0.10.4 ± 0.10.000000--1000 (IU/Kg)0.1 ± 0.00.1 ± 0.00.001000--1600 (IU/Kg)0.2 ± 0.00.3 ± 0.00.001600--2000 (IU/Kg)0.1 ± 0.00.1 ± 0.00.002000--2400 (IU/Kg)0.1 ± 0.00.0 ± 0.00.00TOD: Total daily dose.

Safety and tolerance {#Sec7}
--------------------

No episodes of hypoglycemia requiring medical assistance were reported in either group. All subjects were well served by PN during the study, and no infection event was reported in the two groups.

Discussion {#Sec8}
==========

The management of hyperglycemia during PN was primarily focused on protocol-guided insulin dosing therapy in non-critical care settings^[@CR21]^ or a low-calorie PN regimen^[@CR22]^. There are few studies that have addressed glycemic variation management during PN in diabetic patients.

We conducted a prospective study on patients receiving PN and demonstrated that the CSII therapy could significantly reduce insulin doses and provided further improvement of glycemic fluctuations. Previous studies to assess glycemic control were done mainly by utilizing intermittent fingerpicks. Thus, the 24-hrs blood glycemic excursions are undoubtedly missed by these point-to-point glimpses of blood glucose. CGM provides a unique opportunity to examine the 24-hrs glucose excursions in diabetic patients receiving PN. In the present pilot study, we expected to see better improvement of glycemic variations in the CSII group when compared to the insulin glargine based multiple injections regimen group because the CSII therapy could provide more flexible ways for insulin infusion being compared to insulin administered via injection. Our CGM data showed that patients receiving CSII therapy had significant improvement in MAGE, SD and CV% when compared to those treated with an insulin glargine based multiple injections regimen. GV could be presented by a group of indices originated from the CGM in diabetic patients^[@CR23]--[@CR25]^, such as SD and MAGE, and there is a high degree of correlation between SD and MAGE^[@CR26],[@CR27]^. In this study, the lower SD and MAGE in patients with CSII therapy might contribute to the beneficial effects seen in microvascular and macrovascular complications. It has been observed that acute glucose fluctuations other than chronic hyperglycemia have been shown to play an important role in oxidative stress^[@CR16]^ and nitrosative stress^[@CR15]--[@CR17]^. Interestingly, the improvement of glycemic variations could lead to a significant decreasing of oxidative and nitrosative stress^[@CR28]^. However, in this study, we did not monitor the level of oxidative and nitrosative stresses. We addressed these as limitations in this study. In addition, our data showed that patients receiving the CSII therapy reached glycemic goals significantly earlier than in the MDI groups, and this was in agreement with our previous observations which indicated that newly diagnosed or longstanding T2D patients needed a significantly shorter time to achieve euglycemic control by receiving the CSII therapy when compared to those with MDI therapy^[@CR19]^. Our study demonstrated that insulin administration was not the provider of beneficial effects seen with morbidity and mortality^[@CR29]^. On the contrary, insulin administration played a detrimental role in mortality in patients receiving PN^[@CR30]^. In this study, insulin administered via the CSII therapy which significantly decreased insulin doses when compared to those of glargine based multiple injections groups. Thus, we could infer that the decreased insulin doses administration might contribute to the benefits seen with morbidity and mortality. Future studies are needed to identify the insulin doses which were administered and which had adverse outcomes in patients receiving PN in non-intensive care settings.

It's well established that an elevation in blood glucose was a risk factor for infection^[@CR31]--[@CR33]^. However, we did not observe any infections in this study in either group. This may be a shortcoming of our study, and we are now recognizing this as another limitation of our study.

There is a controversy in the history of diabetes as to whether or not taking a course which could result in additional risk of complications in patients receiving PN should be followed^[@CR4],[@CR5],[@CR34]^. A previous study reported that patients with a history of diabetes had higher levels of blood glucose levels than those in another group^[@CR4]^. We did not observe a higher incidence of hyperglycemia in patients with T2D when patients were compared to others. This might be the results of a modest sample and the limitations of study period.

We also provided a pattern of insulin doses required by patients to achieve the euglycemic control during PN. In this study, our observations were that patients receiving PN required more different pattern of insulin doses to maintain glycemic control, especially during the last 4-hrs period of PN therapy. The reason may partially be the absorption of insulin by PN bags. The percentage lost is very low 90--95%^[@CR35]^. Another observation of importance was that we observed that patients in both groups needed significantly gradually decreased bolus insulin doses to maintain euglycemic control at the endpoint. Future study is needed to identify the discharge of insulin attached to the bags in different infusion time-point during PN. Insulin therapy carries an increase in risks of hypoglycemia and weight gain^[@CR36]--[@CR38]^. However, in this study, subjects in both groups had no events of hypoglycemia or glucose levels less than 3.9 mmol/L monitored by CGM.

The study of the patient population was limited to the Nanjing area in China, and we recognize the results might be different in other geographical regions or populations.

In conclusion, the administration of insulin via CSII led to a significant decrease in glycemic variations, and insulin doses required by patients receiving PN to maintain euglycemic control when compared to the MDI therapy in patients with T2D who had had gastrointestinal surgery.

Methods {#Sec9}
=======

This was a single-center, randomized, open-label trial. The study protocol and patient consent forms were approved by the Institutional Ethical Committee of Nanjing First Hospital, Nanjing Medical University. All procedures followed were in accordance with the ethical standards of Nanjing First Hospital, and with the Helsinki Declaration of 1964 as revised in 2013. Informed consent was obtained from all patients for being included in the study. The study flow chart was described as Fig. [2](#Fig2){ref-type="fig"}.Figure 2Study flow chart.

Between May 2017 and Aug 2017, a total of 102 patients with T2D receiving PN were recruited in Nanjing First Hospital, Nanjing Medical University, China. The inclusion criteria were (1) patients aged between 18 and 80 years; (2), confirmed T2D with history or HbA1c ≥6.5%; (3), body mass index (BMI): 21 to 35 kg/m^2^. Patients were excluded if they had a blood glucose concentration \>200 mg/dL, chronic kidney disease, or were unwilling to participate.

After baseline data were collected, recruited subjects were then randomized in equal numbers to a CSII group or an insulin glargine based MDI without any oral antidiabetic agent for 3--5 days for achieving glycemic control before surgical treatments. When euglycemic control was achieved, operation was performed and treatments were unchanged during the study period in the two groups. From day 1 after surgery, patients were received Fatemulsion, Aminoacids (17) glucose (11) Injection infusions (Kabiveil PI, Sino-Swed Pharmaceutical Corp. Ltd, Wuxi, China) 1440 ml daily, which contains 96 g dextrose. Insulin was added into Kabiveil PI at the ratio of 1:4 to dextrose (24 units insulin were added into the PN) as previously prescribed^[@CR39]^. All PN infusions were started daily at 10:30 and run at a rate of 110 mL/h. Followed by Kabiveil PI infusion, a 5% Glucose Injection Solution (500 mL) was supplied to ensure that the amount of infused dextrose to 150 g/d per day^[@CR40]^. The amount of macronutrient composition was calculated by a PN pharmacist based on each patient's clinical requirements.

Capillary Blood glucose level was tested every 4-hrs by finger prick to titrate insulin dose with a goal of keeping values 4.6--7.8 mmol/dL. Insulin was administered at 1000 in both groups. The insulin Aspart (Novo Nordisk, Bagsværd, Denmark) dose was 0.05 IU/kg/h in CSII group, which was given in two injection modes: 0.01 IU/kg/h was given after PN therapy, the remaining insulin dose was given as a bolus during PN period. Investigators titrated insulin doses every 4-hrs on an individual-patient basis at the titration algorithm. The total daily insulin dose was also 0.5 IU/kg in MDI group, which was given in two injection modes: 1/5 of total daily insulin dose was administered before bedtime as basal dose (Lantus SoloStar; Sanofi-Aventis, Paris, France), the remaining insulin dose was given as a bolus dose (insulin Aspart) based on blood glucose concentrations monitored at 4-hrs interval during PN period. Investigators titrated insulin doses on an individual-patient basis at the titration algorithm (if the blood glucose level was less than 4.4 mmol/L, the basal insulin dose was reduced 2 units; if the blood glucose level was within 4.4 to 6.1 mmol/L, the basal insulin dose was unchanged; if the blood glucose level was within 6.2 to 7.8, 7.9 to 10.0, and \>10.0 mmol/L, the basal insulin dose was increased subsequently by 2, 4, and 6 units, respectively), as we described previously^[@CR19]^.

All patients were subjected to a 4-day retrospective CGM (Medtronic Incorporated, Northridge, USA) from the day euglycemic control achieved, which was performed as previously described^[@CR19],[@CR41]^. After the CGM data was collected, the 24-hrs MG, the SDBG, and the incremental AUC of glucose above 10.0 mmol/L or less than 3.9 mmol/L, and the hourly MBG, the SDBG, and the CV% were calculated by software provided by Medtronic Incorporated, USA. The MAGE was calculated manually for each patient by measuring the arithmetic mean of the ascending and descending excursions between consecutive peaks and nadirs for the same 24-hrs period, and only absolute excursion values \>1 SD were considered, as described previously^[@CR19],[@CR41],[@CR42]^.

To observe the efficacy of CSII or MDI therapy on glycemic variations, the 14-hrs MBG, SDBG, CV(%), MAGE, the incremental AUC of glucose above 10.0 mmol/L or less than 3.9 mmol/L, and the hourly MG during PN period were also recorded and analyzed.

Serum samples were obtained before Kabiveil PI administration for glucose, HbA~1c~ and C-peptide concentration determination. HbA~1c~ was measured by a DiaSTAT HbA~1c~ analyzer (Bio-Rad, Hercules, CA). C-peptide and glucose concentrations were measured centrally at the central laboratory in Nanjing First Hospital, Nanjing Medical University.

The primary endpoint was the MAGE in patients receiving PN therapy. Secondary endpoints were the 24-hrs MG, SDBG, incremental AUC of blood glucose above 10.0 mmol/L or less than 3.9 mmol/L, hourly MG, and insulin doses required by patients to maintain glycemic control.

Statistical Analysis {#Sec10}
--------------------

Statistical analysis was performed using the SPSS software (version 17.0; SPSS, Inc., Chicago, IL). Shapiro-Wilk test was used to assess the distribution of data. Normally distributed and continuous variables are presented as mean (standard deviation, SD). The mixed ANOVA model (2 × 2) test was used to compare the differences within a group. A two way ANOVA was used in the comparisons between groups. Bonferroni correction was followed. P values were two-tailed with a significant level of 5%.
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